Abstract
The spread of vector-borne viruses, such as CHIKV, is a significant public health concern in the Americas, with over 120,000 cases and 51 deaths in 2023, of which 46 occurred in Paraguay. Using a suite of genomic, phylodynamic, and epidemiological techniques, we characterized the ongoing large CHIKV epidemic in Paraguay.
Article Summary Line Genomic and epidemiological characterization of the ongoing Chikungunya virus epidemic in Paraguay
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the PAHO Health Emergencies Department, by the National Institutes of Health USA grant U01 AI151698 for the United World Arbovirus Research Network (UWARN), FAPESP (2021/11944-6) and by Mercosur Structural Convergence Fund (FOCEM), Mercosur, FOCEM agreement N 03/11 Project "Research, Education and Biotechnologies Applied to Health (COF 03/11).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project was reviewed and approved by the Pan American Health Organization Ethics Review Committee (PAHOERC) (Ref. No. PAHO-2016-08-0029) and by the Paraguayan Ministry of Public Health and Social Welfare (MSPyBS/ S.G. no. 0944/18). The samples used in this study were de-identified residual samples from the routine diagnosis of arboviruses in the Paraguayan public health laboratory, which is part of the public network within the Paraguayan Ministry of Health.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
